Target type: biologicalprocess
The chemical reactions and pathways involving any of the forms of vitamin K, quinone-derived vitamins which are involved in the synthesis of blood-clotting factors in mammals. Vitamin K substances share a methylated naphthoquinone ring structure and vary in the aliphatic side chains attached to the molecule. [GOC:jl, http://www.dentistry.leeds.ac.uk/biochem/thcme/vitamins.html#k]
Vitamin K is a fat-soluble vitamin essential for blood clotting and bone health. The metabolic process of vitamin K involves a complex series of enzymatic reactions that occur primarily in the liver. The primary form of vitamin K found in food is phylloquinone (vitamin K1), which is converted to its active form, menaquinone-14 (MK-14), by the enzyme phylloquinone reductase. Menaquinone-14 is then further metabolized to menaquinone-4 (MK-4), the primary form of vitamin K found in the liver and other tissues. The liver is the main site of vitamin K metabolism and storage. Vitamin K is required for the activation of several proteins involved in blood clotting, including prothrombin and factors VII, IX, and X. These proteins are produced in the liver and are inactive until they are carboxylated by the enzyme gamma-glutamyl carboxylase. The carboxylation process involves the addition of a carboxyl group (COOH) to specific glutamic acid residues in these proteins. This carboxylation process requires vitamin K as a cofactor. Vitamin K also plays a role in bone health by regulating the synthesis of osteocalcin, a bone protein that promotes bone mineralization. Osteocalcin is carboxylated by gamma-glutamyl carboxylase in a vitamin K-dependent manner, which is essential for its function. Vitamin K deficiency can lead to a number of health problems, including bleeding disorders, osteoporosis, and bone fractures. The body's requirement for vitamin K varies depending on age, diet, and other factors. Good dietary sources of vitamin K include leafy green vegetables, broccoli, Brussels sprouts, and some vegetable oils.'
"
Protein | Definition | Taxonomy |
---|---|---|
Vitamin K epoxide reductase complex subunit 1 | [no definition available] | Bos taurus (cattle) |
Vitamin K epoxide reductase complex subunit 1-like protein 1 | A vitamin K epoxide reductase complex subunit 1-like protein 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8N0U8] | Homo sapiens (human) |
Vitamin K epoxide reductase complex subunit 1 | A vitamin K epoxide reductase complex subunit 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9BQB6] | Homo sapiens (human) |
Vitamin K epoxide reductase complex subunit 1-like protein 1 | A vitamin K epoxide reductase complex subunit 1-like protein 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q8N0U8] | Homo sapiens (human) |
Vitamin K-dependent gamma-carboxylase | A vitamin K-dependent gamma-carboxylase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P38435] | Homo sapiens (human) |
Carbonyl reductase [NADPH] 1 | A carbonyl reductase [NADPH] 1 that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
NAD | An NAD(P)H dehydrogenase [quinone] 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P15559] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
4'-bromoflavone | 4'-bromoflavone: structure in first source | ||
beta-naphthoflavone | beta-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the f side of flavone. beta-Naphthoflavone: A polyaromatic hydrocarbon inducer of P4501A1 and P4501A2 cytochromes. (Proc Soc Exp Biol Med 1994 Dec:207(3):302-308) | extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound | aryl hydrocarbon receptor agonist |
haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
beta-lapachone | beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities. beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase | benzochromenone; orthoquinones | anti-inflammatory agent; antineoplastic agent; plant metabolite |
vitamin k 3 | Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo. | 1,4-naphthoquinones; vitamin K | angiogenesis inhibitor; antineoplastic agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; human urinary metabolite; nutraceutical |
sulforaphane | sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen. sulforaphane: from Cardaria draba L. | isothiocyanate; sulfoxide | antineoplastic agent; antioxidant; EC 3.5.1.98 (histone deacetylase) inhibitor; plant metabolite |
triclosan | aromatic ether; dichlorobenzene; monochlorobenzenes; phenols | antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic | |
daunorubicin | anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine. daunorubicin : A natural product found in Actinomadura roseola. Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. | aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones | antineoplastic agent; bacterial metabolite |
c 1303 | C 1303: DNa-binding drug; structure given indicates that the cpd should be the dimethylamino cpd, but it is named as the diethylamino cpd | ||
nsc 366140 | NSC 366140: a 9-methoxypyrazoloacridine; structure given in first source | ||
naringenin | (S)-naringenin : The (S)-enantiomer of naringenin. | (2S)-flavan-4-one; naringenin | expectorant; plant metabolite |
5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione | 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione: structure in first source | ||
biochanin a | 4'-methoxyisoflavones; 7-hydroxyisoflavones | antineoplastic agent; EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor; phytoestrogen; plant metabolite; tyrosine kinase inhibitor | |
vitamin k1 oxide | vitamin K1 oxide: RN given refers to parent cpd; see also record for 2,3-epoxymenaquinone | ||
chrysin | chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7. | 7-hydroxyflavonol; dihydroxyflavone | anti-inflammatory agent; antineoplastic agent; antioxidant; EC 2.7.11.18 (myosin-light-chain kinase) inhibitor; hepatoprotective agent; plant metabolite |
wedelolactone | wedelolactone : A member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3. wedelolactone: antihepatotoxic coumestan from Eclipta prostrata and Wedelia calendulacea (both Asteraceae); structure given in first source | aromatic ether; coumestans; delta-lactone; polyphenol | antineoplastic agent; apoptosis inducer; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; hepatoprotective agent; metabolite |
menatetrenone | menaquinone-4 : A menaquinone whose side-chain contains 4 isoprene units in an all-trans-configuration. | menaquinone | anti-inflammatory agent; antioxidant; bone density conservation agent; human metabolite; neuroprotective agent |
bisantrene | |||
4,3',5'-tri-o-methylpiceatannol | |||
monorden | monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II | cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols | antifungal agent; metabolite; tyrosine kinase inhibitor |
memoquin | memoquin: structure in first source | ||
dicumarol | Dicumarol: An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases. | hydroxycoumarin | anticoagulant; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; Hsp90 inhibitor; vitamin K antagonist |
warfarin | 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice. Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. | benzenes; hydroxycoumarin; methyl ketone | |
ethyl biscoumacetate | Ethyl Biscoumacetate: A coumarin that is used as an anticoagulant. It has actions similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226) | hydroxycoumarin | |
nsc 158393 | NSC 158393: structure given in first source |